Loss of function STK11 alterations and poor outcomes in non–small-cell lung cancer: Literature and case series of US Veterans
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference43 articles.
1. Non–small cell lung cancer in the era of immunotherapy;Kheradmand;Semin Oncol,2021
2. Non-Small Cell Lung Cancer NCCN Evidence Blocks,2022
3. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non–small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial;Felip;Lancet Lond Engl,2021
4. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial;Faivre-Finn;J Thorac Oncol,2021
5. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189;Rodríguez-Abreu;Ann Oncol,2021
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prognostic implications of STK11 with different mutation status and its relationship with tumor-infiltrating immune cells in non-small cell lung cancer;Frontiers in Immunology;2024-04-26
2. Antineoplastics;Reactions Weekly;2023-06-24
3. KRAS: Druggable at Last;The Oncologist;2023-03-18
4. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival;JCO Precision Oncology;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3